On April 6, 2023, the U.S. Food and Drug Administration announced the final decision to withdraw approval of Makena. Makena was approved to reduce the risk of preterm birth in pregnant women. Expanded outcome data showed that Makena is not effective.
As of April 7, 2023, Makena, its generics and hydroxyprogesterone caproate compounded products are not a covered benefit for Blue Cross Blue Shield of North Dakota Commercial or Medicaid Expansion members per the terms of the benefit plans.
The medical policies for the hydroxyprogesterone caproate injection as a technique to reduce preterm birth in high-risk pregnancies have been updated to reflect Makena, its generics and hydroxyprogesterone caproate compounded products as non-covered as of April 7, 2023.
Please refer to the updated medical policies:
- Hydroxyprogesterone Caproate Injection as a Technique To Reduce Preterm Birth in High-Risk Pregnancies | BCBSND
- Hydroxyprogesterone Caproate Injection as a Technique To Reduce Preterm Birth in High-Risk Pregnancies (Medicaid Expansion) | BCBSND
Contact our Commercial Provider Service Center at 1-800-368-2312 or Medicaid Expansion Provider Service Center at 1-833-777-5779 for additional information.